Immunoglobulin G (IgG) molecules remain the backbone of many antibody therapeutics, requiring precise control of glycosylation, structural integrity, and scalable purification processes. Avid supports IgG programs through optimized mammalian cell line development and disciplined CGMP manufacturing aligned for long-term performance.
Yes. With optimized expression systems and validated CGMP processes, IgG therapeutics can transition seamlessly from early clinical production to commercial manufacturing.
IgGs are commonly expressed in mammalian systems such as CHO cells to support proper folding, post-translational modifications, and biological function.
IgG therapeutics require careful control of glycosylation, aggregation, and charge heterogeneity to maintain potency and safety, particularly during scale-up.
Advance Your IgG Program with Confidence
Connect with our team to discuss development timelines, manufacturing strategy, and scalable CGMP production.
